TXG stock sentiment today10x Genomics, Inc.

A dominant market leader in single-cell genomics facing a 'valuation vs. reality' reckoning despite strong product adoption of the Atera platform.

Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for TXG. Not financial advice.

The narrative is a tug-of-war between technical enthusiasm for the new Atera spatial biology platform and deep skepticism regarding a 485% yearly run-up. While AI-driven drug discovery demand is a tailwind, recent double-digit daily drops suggest a 'priced to perfection' correction.

• ·Atera platform demand and AI integration
• ·Overvaluation concerns after massive 1-year rally
• ·Recent 13% single-day volatility triggering stop-losses
• ·Anticipation of London management presentation on Nov 17

TXG boasts high gross margins (~60%+) and a strong cash position but remains net-loss generating. Growth is accelerating via recurring consumable revenue, yet the P/S ratio remains significantly elevated compared to historical medians.

• ·High R&D spend as % of revenue
• ·Strong liquid balance sheet with minimal debt
• ·Negative PE ratio due to lack of GAAP profitability
• ·Double-digit revenue growth supported by spatial biology segment

Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.

Mixed conviction — no decisive signal from insiders or the holder base.

• ·Insiders sold a net $5.5M on the open market in the last 120 days.

Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.

• ·Intense patent litigation environment with NanoString and others
• ·High cash burn rate delaying break-even timeline
• ·Extreme valuation sensitivity to interest rate fluctuations
• ·Market saturation in the high-end single-cell niche

How direct competitors stack up against TXG right now.

• COLD
  ILMNIllumina, Inc.

  COLDER — struggling with Grail-related regulatory fallout and sluggish core sequencing growth compared to TXG's innovation curve.

  See full analysis →
• COLD
  NSTGNanoString Technologies

  COLDER — facing severe financial distress and legal setbacks in patent battles against TXG, making them a high-risk laggard.

  See full analysis →
• HOT
  AKYAAkoya Biosciences

  HOTTER — trading at a much lower revenue multiple while offering a pure-play entry into the fast-growing spatial phenotyping market.

  See full analysis →

Consensus average of 16 analysts · median 70.00

Source: StockAnalysis.com · updated 2026-10-23

• Trefis
  Will TXG Stock Ever Get Back To Its Old High?
• Yahoo Finance
  10x Genomics (TXG) Stock Looks Expensive On Its 485% One Year Run
• Moomoo
  10x Genomics (TXG) Stock Forecast & Analyst Ratings
• GuruFocus
  10x Genomics Inc (TXG) Stock Up 7.2% but GF Value Says Overvalued -- GF Score: 60/100
• Seeking Alpha
  10x Genomics: Atera Takes Off, But Valuation Flies Too High (NASDAQ:TXG)
• Quiver Quantitative
  $TXG stock is down 13% today. Here's what we see in our data.